Using specific drugs to improve treatment outcomes for glioblastoma patients
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA LOS ANGELES · NIH-11001112
This study is looking at how specific drugs can make radiation therapy work better for people with glioblastoma, a type of brain cancer, by figuring out the best combinations to use for more personalized treatment plans.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA LOS ANGELES (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-11001112 on ClinicalTrials.gov |
What this research studies
This research investigates how certain compounds from the NCI CTEP portfolio can be used to enhance the effectiveness of radiation therapy for glioblastoma, a type of brain cancer. The approach focuses on understanding how these drugs can prevent changes in cancer cell behavior that make treatment less effective. By analyzing biomarkers, the study aims to identify which drug combinations work best with radiation therapy, potentially leading to more personalized treatment plans for patients. The research will involve both laboratory studies and in vivo testing to validate the findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing or considering radiation therapy.
Not a fit: Patients with other types of brain tumors or those who are not candidates for radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better treatment options for glioblastoma patients.
How similar studies have performed: Previous research has shown promise in using combination therapies to enhance treatment outcomes in glioblastoma, suggesting that this approach could be effective.
Where this research is happening
LOS ANGELES, UNITED STATES
- UNIVERSITY OF CALIFORNIA LOS ANGELES — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PAJONK, FRANK — UNIVERSITY OF CALIFORNIA LOS ANGELES
- Study coordinator: PAJONK, FRANK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.